A zebrafish ALS model identified tribenzylamine as a candidate compound
Original source
FUS-driven zebrafish model of ALS identifies tribenzylamine as a candidate modulator of ALS-associated pathology. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Animal
Related topics
Researchers used zebrafish carrying a disease-associated FUS mutation to screen for compounds affecting ALS-related features. Tribenzylamine improved movement and reduced reactive oxygen species in the fish, alongside changes in gene activity and hormone-related signalling. The findings are from an animal model and do not establish a treatment for people with ALS.
Why this matters
The study provides a platform for testing potential ALS compounds and identifies tribenzylamine for further research. It may be relevant to researchers studying FUS-associated ALS, but it does not currently change treatment for people living with ALS.
Limitations and context
This was primary research in genetically modified zebrafish, not a human clinical study. The source does not report whether tribenzylamine is safe or effective in people, or whether the findings apply beyond FUS-associated disease. Further laboratory and clinical studies would be needed.